China 2026 Life Sciences Compliance: New Enforcement Rules, Lower Bribery Thresholds
In-house counsel for life sciences companies operating in China must prioritize compliance updates because regulators have released 2026 sector enforcement priorities, new binding sales rep rules, and lowered criminal bribery thresholds that expand liability risk.
In the first half of 2026, Chinese regulators released a joint 2026 work plan targeting misconduct in pharmaceutical procurement, medical services, and related areas, elevating medical data security and investigator-initiated study oversight to standalone enforcement priorities. New binding rules for pharmaceutical sales representatives take effect August 1, 2026, with a public violation disclosure platform already active. A new judicial interpretation lowers criminal bribery thresholds for the life sciences sector to RMB 100,000 for individuals and RMB 200,000 for entities, and creates clearer corporate liability for employee misconduct approved by senior management. Companies should update compliance programs to cover third-party research arrangements, sales rep filing requirements, distributor tax invoice vetting, and medical insurance fund use to mitigate expanded multi-agency enforcement risk.